Alaska Permanent Fund’s Regeneron Pharmaceuticals REGN Stock Holding History

Alaska Permanent Fund’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,624	Closed	-$2.77M	–	353
2025 Q1	$2.77M	Hold	4,624	–	–	0.04%	201
2024 Q4	$3.29M	Hold	4,624	–	–	0.05%	172
2024 Q3	$4.86M	Hold	4,624	–	–	0.07%	113
2024 Q2	$4.99M	Buy	4,624 +720	+18%	+$698K	0.07%	114
2024 Q1	$3.76M	Buy	3,904 +58	+2%	+$55.2K	0.06%	130
2023 Q4	$3.38M	Buy	3,846 +1,641	+74%	+$1.35M	0.06%	128
2023 Q3	$1.81M	Buy	2,205 +1,720	+355%	+$1.35M	0.03%	312
2023 Q2	$348K	Buy	+485	New	+$374K	0.01%	361
2022 Q4	$267K	Buy	370 +2	+0.5%	+$1.48K	﹤0.01%	325
2022 Q3	$253K	Buy	368 +58	+19%	+$36.5K	﹤0.01%	319
2022 Q2	$183K	Sell	310 -4,838	-94%	-$3.14M	﹤0.01%	322
2022 Q1	$3.6M	Sell	5,148 -18	-0.3%	-$11.4K	0.06%	44
2021 Q4	$3.14M	Buy	5,166 +166	+3%	+$102K	0.06%	43
2021 Q3	$3.03M	Hold	5,000	–	–	0.06%	46
2021 Q2	$2.79M	Buy	+5,000	New	+$2.53M	0.05%	37

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alaska Permanent Fund's REGN Position: Q2 2025 in Review

Alaska Permanent Fund sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 4,624 shares — an estimated $2.77M sold.

Alaska Permanent Fund first reported a position in REGN in Q2 2021 and held it in 15 quarters. The position peaked at $4.99M in Q2 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Alaska Permanent Fund reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Alaska Permanent Fund sold 4,624 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $2.77M.
Alaska Permanent Fund first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 15 quarters.
Alaska Permanent Fund's Regeneron Pharmaceuticals position peaked at $4.99M in Q2 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Alaska Permanent Fund's 13F filing for Q2 2025, filed 14 Aug 2025.